Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that enrollment in its Phase 3 APPROACH clinical trial has surpassed 86% and remains on track. The study is evaluating HLP003, the company's lead proprietary novel serotonergic agonist (NSA), as an adjunctive treatment for major depressive disorder (MDD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address a significant unmet medical need.
The APPROACH study is part of the broader Phase 3 PARADIGM program, which also includes the EMBRACE study and the EXTEND long-term extension study. Helus Pharma stated that the enrollment milestone supports its goal of reporting topline data from APPROACH in the fourth quarter of 2026, advancing HLP003 toward potential commercialization. This progress is critical for the approximately 21 million adults in the U.S. who experience at least one major depressive episode annually, many of whom do not respond adequately to existing treatments.
For business and technology leaders, the implications are twofold. First, successful development of HLP003 could reshape the mental health treatment landscape, offering a novel mechanism that promotes neuroplasticity via serotonin pathway activation. This could reduce the economic burden of MDD, which costs the U.S. economy over $210 billion annually in lost productivity and healthcare expenses. Second, Helus Pharma's use of proprietary NSAs represents a technological advancement in psychopharmacology, potentially setting a new standard for drug development in mental health.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing NSAs for depression, anxiety, and other mental health conditions. Beyond HLP003, the company is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder, and maintains an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland.
For investors and industry observers, the APPROACH trial's enrollment milestone is a key de-risking event. With Breakthrough Therapy Designation, HLP003 may qualify for expedited regulatory review, potentially accelerating time to market. However, the trial's success hinges on demonstrating statistically significant efficacy and safety compared to placebo. The company's ability to maintain enrollment momentum and meet the 2026 data readout will be closely watched.
More information about Helus Pharma can be found at www.helus.com, and the latest news is available in the company's newsroom at https://ibn.fm/HELP.
